COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01902225
Recruitment Status : Active, not recruiting
First Posted : July 18, 2013
Last Update Posted : August 13, 2019
Celgene Corporation
Information provided by (Responsible Party):
Weiyun Ai, University of California, San Francisco

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : July 11, 2018
Estimated Study Completion Date : April 1, 2020